Navigation Links
Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
Date:6/18/2008

ctations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the diagnosis and treatment of disease and the expected timing of submission for approval and launch of diagnostic tests using its microRNA technology, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: Rosetta's approach to discover microRNA technology and to work on the application of this technology in the development of novel diagnostics and therapeutic tools, which is unproven and may never lead to marketable products or services, including development of tests for predicting response to ovarian cancer treatment, risk of gastric cancer recurrence, differentiation of small from non-small cell lung cancer and identification of unique microRNA biomarkers for colon cancer,; Rosetta's ability to fund and the results of further pre-clinical and clinical trials; Rosetta's ability to obtain, maintain and protect the intellectual property utilized by Rosetta's products; Rosetta's ability to enforce its patents against infringers and to defend its patent portfolio against challenges from third parties; Rosetta's ability to obtain additional funding to support its business activities; Rosetta's dependence on third parties for development, manufacture, marketing, sales, and distribution of products; Rosetta;s ability to acquire and successfully operate a CLIA-certified laboratory; Rosetta's ability to successfully develop its candidate tools, products and services, all of which are in early stages of development; Rosetta's ability to obtain regulatory clearances or approvals that may be required for its products and services; Rosetta's ability to obtain
'/>"/>
SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... Aug. 1, 2014 One of the major ... personalized medicine, which is the practice of using genomic ... a patient,s individual biology. Personalized diagnostics—laboratory analyses that inform ... in the lab,s future. This fall, AACC ,s ... latest science in this exciting field and the novel ...
(Date:8/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals in its ... MARKETS , that the global market RNA interference (RNAi) ... $38.8 billion by 2018, with a five-year compound annual ... the fastest moving segment of the market, is moving ... RNAi therapeutics has shown tremendous growth and has moved ...
(Date:7/31/2014)... (PRWEB) August 01, 2014 ... China Polyurethane Resin Industry” is a professional ... market. The report introduces Polyurethane Resin basic ... industry chain structure and industry overview. This ... China’s domestic market as well as global ...
(Date:7/31/2014)... see through organs and even the entire body to ... cellular structures has been a long-time dream of biologists. ... 31st in the journal Cell has now ... making opaque organs, bodies, and human tissue biopsies transparent, ... protocols could pave the way for a better understanding ...
Breaking Biology Technology:First-Ever AACC Virtual Conference to Focus on Personalized Diagnostics 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 2Global Market for RNAi Drug Delivery Technologies to Reach $38.8 Billion in 2018; Aptamer Delivery Segment Surging at 58.2% CAGR 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 2Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 3Polyurethane Resin Industry & Thermoplastic Polyurethane Market (China, Global) Analysis Now at DeepResearchReports.com 4See-through organs and bodies will accelerate biomedical discoveries 2
... , SAN FRANCISCO, Aug. 11 ... stage biopharmaceutical company developing a proprietary breakthrough class of targeted ... private placement financing with gross proceeds of US $5,123,521, exceeding ... anticipated on or before September 15, 2009, with additional proceeds ...
... , , CAMBRIDGE, Mass., Aug. 11 ... of novel therapies for immune-mediated diseases, today announced changes to the protocol ... and efficacy of otelixizumab, a targeted T cell immunomodulator, in patients with ... ( D urable Response Therapy E valuation F or ...
... SEATTLE, Aug. 11 Omeros Corporation today announced ... OMS302, the Company,s ophthalmologic PharmacoSurgery(TM) product candidate. OMS302 is ... agent that causes pupil dilation (mydriasis), each with well-known ... Omeros, Phase 1/Phase 2 trial enrolled 61 patients undergoing ...
Cached Biology Technology:Jennerex Closes $5 Million First Tranche of Series C Financing 2Tolerx Announces Amendment to Phase 3 DEFEND Protocol 2Tolerx Announces Amendment to Phase 3 DEFEND Protocol 3Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery 2
(Date:7/31/2014)... enormous conflagration known as the Rim Fire was in ... mature trees, when it entered the backcountry of Yosemite ... 2013. But inside the park, the battle began to ... decisions and drought can combine to fuel large, severe ... it eventually encountered lands where fire had been used ...
(Date:7/31/2014)... are familiar with Hibiscus flowers- they are an ... are commonly planted in the landscape. Some, like ... endangered species. , Only a relatively few botanists ... an equally beautiful and intriguing related group of ... of Hibiscus". , Brother of Hibiscus species are ...
(Date:7/31/2014)... White, brown and beige adipocytes, or fat cells, are ... functions and each plays its own role in metabolism. ... far the most prevalent. Its primary function is energy ... energy to generate heat but are only found in ... adipocytes, which represent a special type of brown adipocytes, ...
Breaking Biology News(10 mins):The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5Brother of Hibiscus is found alive and well on Maui 2Hope for the overweight 2
... Washington, DC Engineered nanoscale materials (ENMs), which ... use in food packaging, raise new safety evaluation ... report released today by the Project on Emerging ... The food-packaging industry, food companies and ...
... developed an effective technology for reducing contamination of dangerous ... Salmonella and E. coli O157:H7 on foods ranging from ... It is made from inexpensive and readily available ingredients ... and Drug Administration. The new technology, which ...
... Almost every June for 30 years, Terry McEneaney drove around ... three routes. Park ornithologist at the time, he would ... Then he,d drive another half mile, repeat the process and ... for the North American Breeding Bird Survey. Trying to finish ...
Cached Biology News:Use of nanomaterials in food packaging poses regulatory challenges 2New UGA invention effectively kills foodborne pathogens in minutes 2Bird watchers, space technology come together in Montana State University study 2Bird watchers, space technology come together in Montana State University study 3
Recombinant Rhesus Macaque IFN-alpha...
chk 1 kinase...
...
KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
Biology Products: